A Prediction Model of Early Diabetic Nephropathy Based on Conventional Ultrasound Parameters and Hematological Indices and Its Application
DOI:
https://doi.org/10.52547/bvgedh79Keywords:
Ultrasonic parameters, Hematological index, Early diabetic nephropathy, Prediction modelAbstract
Introduction. Diabetic nephropathy (DN) is a chronic microvascular complication of diabetes mellitus, leading to end-stage kidney disease and increased mortality. Early detection and treatment are essential to prevent DN. This study aims to develop a diagnostic prediction model for early DN.
Methods. This retrospective analysis study was conducted on 205 patients with type 2 diabetes mellitus (T2DM) treated between September 2019 and September 2022. Patients with stage A1 albumin-to-creatinine ratio (ACR) (< 30 mg/g) were categorized as the simple diabetes mellitus group (n = 134), and those with ACR 30-300 mg/g at stage A2 were classified as the early diabetic nephropathy group (n = 71). Relevant ultrasound parameters and hematological indices were selected through univariate and multivariate screenings. A nomogram model was constructed based on the results of multi-factor screening. Internal validation was performed by using Bootstrap methods with 1000 repetitions, receiver operating characteristic (ROC) curve analysis evaluated model differentiation, calibration curves verified model consistency, and decision curve analysis assessed clinical utility.
Results. Multivariate logistic regression identified renal artery resistance index (RI), renal cortex shear wave velocity (SWV), Cystatin C (CysC), Retinol-binding protein (RBP), and Glycated Hemoglobin (HbA1C) as significant factors for early DN (all P < .05). The nomogram model showed good differentiation and consistency and has high clinical value and practicality in predicting DN.
Conclusion. The prediction model for early DN, based on conventional ultrasound parameters and hematological indices, demonstrates good prediction efficiency and clinical practicability.
Downloads
References
1. Hukportie DN, Li FR, Zhou R, et al. Anthropometric Measures and Incident Diabetic Nephropathy in Participants With Type 2 Diabetes Mellitus. Front Endocrinol (Lausanne). 2021; 12: 706845.
2. Desai N, Koppisetti H, Pande S, et al. Nanomedicine in the treatment of diabetic nephropathy. Future Med Chem. 2021; 13(7): 663-686.
3. Sanchez-Alamo B, Shabaka A, Cachofeiro V, et al. Serum interleukin-6 levels predict kidney disease progression in diabetic nephropathy. Clin Nephrol. 2022; 97(1): 1-9.
4. Yang M, Wang X, Han Y, et al. Targeting the NLRP3 Inflammasome in Diabetic Nephropathy. Curr Med Chem. 2021; 28(42): 8810-8824.
5. Tavares G, Venturini G, Padilha K, et al. 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics. Metabolomics. 2018; 14(4): 39.
6. Pereira PR, Carrageta DF, Oliveira PF, et al. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med Res Rev. 2022; 42(4): 1518-1544.
7. Tavares G, Venturini G, Padilha K, et al. 1,5-Anhydroglucitol predicts CKD progression in macroalbuminuric diabetic kidney disease: results from non-targeted metabolomics. Metabolomics. 2018; 14(4): 39.
8. American Diabetes Association.2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41(1): S13–S27.
9. Gaitonde DY, Cook DL, Rivera IM. Chronic Kidney Disease: Detection and Evaluation. Am Fam Physician. 2017; 96(12): 776-783.
10. Qi C, Mao X, Zhang Z, Wu H. Classification and Differential Diagnosis of Diabetic Nephropathy. J Diabetes Res. 2017; 2017: 8637138.
11. Tofte N, Lindhardt M, Adamova K, et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2020; 8(4): 301-312.
12. Veneti S, Tziomalos K. The Role of Finerenone in the Management of Diabetic Nephropathy. Diabetes Ther. 2021; 12(7): 1791-1797.
13. Sugahara M, Pak WLW, Tanaka T, et al. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton). 2021; 26(6): 491-500.
14. Raparia K, Usman I, Kanwar YS. Renal morphologic lesions reminiscent of diabetic nephropathy. Arch Pathol Lab Med. 2013; 137(3): 351-9.
15. Liu X, Li N, Xu T, et al. Effect of renal perfusion and structural heterogeneity on shear wave elastography of the kidney: an in vivo and ex vivo study. BMC Nephrol. 2017; 18(1): 265.
16. Fuernau G, Poenisch C, Eitel I, et al. Prognostic impact of established and novel renal function biomarkers in myocardial infarction with cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial. Int J Cardiol. 2015; 191: 159-66.
17. Tio MC, Shafi T, Zhu X, et al. Traditions and innovations in assessment of glomerular filtration rate using creatinine to cystatin C. Curr Opin Nephrol Hypertens. 2023; 32(1): 89-97.
18. Christiadi D, Simpson C, O'brien K, et al. Cystatin C kidney functional reserve: a simple method to predict outcome in chronic kidney disease. Nephrol Dial Transplant. 2022; 37(6): 1118-1124.
19. Zhao P, Li N, Lin L, et al. Correlation between serum cystatin C level and renal microvascular perfusion assessed by contrast-enhanced ultrasound in patients with diabetic kidney disease. Ren Fail. 2022; 44(1): 1732-1740.
20. Salisbury D, Bronas U. Reactive oxygen and nitrogen species: impact on endothelial dysfunction. Nurs Res. 2015; 64(1): 53-66.
21. Zhu Y, Wang X, Wang W, et al. Expression and influence of pentraxin-3, HbAlc and ApoA1/ApoB in serum of patients with acute myocardial infarction combined with diabetes mellitus type 2. Exp Ther Med. 2018; 15(5): 4395-4399.
22. Zhou Y, Qi C, Li S, et al. Diabetic Nephropathy Can Be Treated with Calcium Dobesilate by Alleviating the Chronic Inflammatory State and Improving Endothelial Cell Function. Cell Physiol Biochem. 2018; 51(3): 1119-1133.
23. Mahfouz MH, Assiri AM, Mukhtar MH. Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Retinol-Binding Protein 4 (RBP4) in Type 2 Diabetic Patients with Nephropathy. Biomark Insights. 2016; 11: 31-40.
24. Zhang L, Cheng YL, Xue S, et al. The Role of Circulating RBP4 in the Type 2 Diabetes Patients with Kidney Diseases: A Systematic Review and Meta-Analysis. Dis Markers. 2020; 2020: 8830471.
25. Sang-Ho Jeong, Rock Bum Kim, Sun Yi Park, et al. Nomogram for predicting gastric cancer recurrence using biomarker gene expression. European Journal of Surgical Oncology. 2020; 46(1): 195-201.
